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Abstract
Ceragenin CSA-13, a cationic steroid, is here reported to show a concentration-dependent bactericidal/bacteriolytic activity
against pathogenic streptococci, including multidrug-resistant Streptococcus pneumoniae. The autolysis promoted by CSA-
13 in pneumococcal cultures appears to be due to the triggering of the major S. pneumoniae autolysin LytA, an N-
acetylmuramoyl-L-alanine amidase. CSA-13 also disintegrated pneumococcal biofilms in a very efficient manner, although at
concentrations slightly higher than those required for bactericidal activity on planktonic bacteria. CSA-13 has little hemolytic
activity which should allow testing its antibacterial efficacy in animal models.
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Introduction
Despite advances in medicine, infectious diseases remain a
major cause of death and inflict social and economic upheaval on
millions of people worlwide. Respiratory infections alone are
responsible for 4 million deaths every year, with Streptococcus
pneumoniae the predominant causal agent [1]. Indeed, it is the
leading cause of non-invasive infections such as bacterial
pneumonia, sinusitis and otitis media (all biofilm-related infections
[2]), and is commonly the culprit in life-threatening invasive
conditions such as bacteremia/sepsis and meningitis. In develop-
ing countries, pneumococcal septicemia is a major cause of infant
mortality, leading to the deaths of more than 1.2 million infants
every year [3]. HIV infection, sickle-cell anemia, and a variety of
chronic organ failure conditions, increase the risk of serious
pneumococcal disease.
The alarming, global increase in multidrug resistance, partic-
ularly in pneumococcal strains resistant to b-lactams, macrolides,
tetracyclines and sulfonamides, has renewed interest in the
development of novel drugs and strategies for controlling the
spread of antibiotic resistant bacteria [4]. Ceragenins, also known
as CSAs (for Cationic Steroid Antibiotics), are based on a cholic
acid scaffolding, and mimic antimicrobial peptides [5]. Ceragen-
ins, however, are easier to synthesize than the latter and are much
more stable. Further, since they are not peptide-based, they are
free from breakdown by proteases, a phenomenon that limits the
lifetimes of antimicrobial peptides. Under physiological conditions,
ceragenins are polycationic; they therefore associate strongly with
anionic bacterial cell surfaces, displacing patches of the membrane
[6]. This causes a loss of membrane integrity along with changes in
its permeability, eventually leading to the death of affected cells.
Ceragenins show strong bactericidal activity against Gram-
negative and Gram-positive bacteria (mainly enterococci and
staphylococci), and there is little likelihood that natural resistance
can be generated against them. It has also been reported that
ceragenins potentiate the effect of certain antibiotics on planktonic
cells, as well as on mature biofilms produced by a number of
Pseudomonas aeruginosa strains [7].
The present work examines the antimicrobial activity of the
most potent ceragenin, CSA-13 (Fig. 1), against planktonic
cultures and biofilms of S. pneumoniae and other pathogenic
streptococci.
Materials and Methods
Ethics statement
The study was submitted to the Consejo Superior de
Investigaciones Cientı´ficas (CSIC) Ethics Committee which
declared it to be carried out with the appropriate ethical
safeguards.
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Bacterial strains and growth conditions
The streptococcal strains used in this study are listed in Table 1.
These were routinely grown in C medium [8] supplemented (or
not) with 0.08% yeast extract (C+Y medium), at 37uC without
shaking, or on reconstituted tryptose blood agar base plates (Difco
Laboratories) supplemented with 5% defibrinated sheep blood.
Escherichia coli BL21(DE3) (pMMN1) [9] was grown in Luria-
Bertani (LB) medium with ampicillin (100 mg/ml) [10] at 37uC
with aeration, as a source of the major pneumococcal autolysin
LytA, an N-acetylmuramoyl-L-alanine amidase (NAM-amidase;
EC 3.5.1.28) [11].
Transformation procedures
S. pneumoniae R6 was transformed with chromosomal DNA from
the pneumococcal R924 strain (lytA::aphIII) [12] by treating
precompetent cells with 100 ng/ml of synthetic competence-
stimulating peptide 1 (CSP1), as previously described [13].
Transformants were selected by plating in CAT agar supplement-
ed with 3% defibrinated sheep blood, followed by challenge with a
10 ml overlay containing kanamycin (250 mg/ml) [14].
Antibacterial susceptibility assays
The antibacterial activity of CSA-13, kindly provided by P.B.
Savage (Department of Chemistry and Biochemistry, Brigham
Young University, Provo, Utah, USA), was determined by
standard macrodilution methods according to the Clinical and
Laboratory Standards Institute guidelines using an inoculum of
<46105 CFU/ml [15]. The MIC was defined as the lowest
concentration of CSA-13 that prevented visible growth after 24 h
of culture in Mueller-Hinton broth supplemented with 2.5% lysed
horse blood (Oxoid), or C medium, at 37uC.
Time-kill experiments
Unless otherwise stated, exponentially growing cultures of the
streptococcal strains were incubated in C+Y medium to an
absorbance at 550 nm (A550) of about 0.2 corresponding to
approximately 1–26108 CFU/ml, depending on the streptococcal
strain. CSA-13 was then added at different concentrations to
aliquots of the culture, and incubation continued without shaking
at 37uC. Growth and lysis were monitored via A550 values. The
viability of a bacterial population was assessed by colony counting
on blood agar plates and/or visualized by fluorescence microsco-
py, using the LIVE/DEAD BacLight bacterial viability kit
(Invitrogen-Molecular Probes) to stain cells over a 15 min period
in the dark. Bacteria were observed at 640 and 6100
magnifications using a Leica DM4000B fluorescence microscope
equipped with L5 (bandpass 480/40) and N2.1 (bandpass 515–
560) filter sets for SYTO 9 and propidium iodide (PI). Both stains
are nucleic acid-binding agents but they differ in their spectral
characteristics and their ability to penetrate viable bacterial cells.
SYTO 9 stains all cells green, while propidium iodide penetrates
those with a damaged cell membrane, staining them red.
Biofilm formation assay
The conditions adopted for biofilm formation by pneumococcal
cells and other streptococci in 96-well polystyrene microtiter plates
(Costar 3595, Corning Inc.) were those previously described [14].
Cells in late exponential growth were diluted in fresh C medium
and about 4.56106 CFU were dispensed into each well. After 6 h
of incubation at 34uC, the biofilm formed was stained with 0.2%
crystal violet for 15 min and rinsed to remove non-adherent
bacteria. After solubilizing the biofilm in 95% ethanol, the A595
was determined using an Anthos 2020 microplate absorbance
reader (Anthos Labtec Instruments).
For observation of the biofilms by confocal laser scanning
microscopy (CLSM), bacteria (about 4.56104 CFU) were grown
on glass-bottom dishes (WillCo-dish, WillCo Wells B.V.) for 12 h
at 34uC and then stained with the LIVE/DEAD BacLight
bacterial viability kit. The biofilms were observed at 6100
magnification using a Leica TCS-SP2-AOBS-UV CLSM
equipped with an argon ion laser. The excitation/emission
maxima were around 480/500 and 490/653 nm for SYTO 9
and PI respectively. Images were analyzed using LCS software
(Leica). Projections were obtained in the x–y (scans at 0.5 mm
intervals) and x–z planes (scans at 3 mm intervals).
Expression and purification of NAM-amidase LytA
Escherichia coli BL21(DE3) (pMMN1) was incubated in LB
medium containing ampicillin (100 mg/ml) and 0.4 mM isopro-
pyl-b-D-thiogalactopyranoside for the overproduction of LytA,
following the previously described protocol [9]. After bacterial
disruption in a French pressure cell press, the insoluble fraction
was separated by ultracentrifugation (100,0006g, 1 h, 4uC), and
the supernatant loaded into a DEAE-cellulose column to purify
the LytA protein in a single step [16]. The purified enzyme was
dialyzed against 20 mM sodium phosphate buffer, pH 6.9, and the
protein concentration determined spectrophotometrically.
Enzymatic assay of LytA activity using radioactively
labeled cell walls
Pneumococcal cell walls were radioactively labeled with
[methyl-3H] choline as previously described [17]. Cell wall
degradation assays were performed according to standard
procedures [18], measuring the amount of radioactivity released
into the supernatant. One unit (U) of enzymatic activity was
defined as the amount of enzyme needed to release 1 mg (about
700 net cpm) of labeled cell wall material in 10 min at 37uC.
Figure 1. Structure of the ceragenin CSA-13.
doi:10.1371/journal.pone.0101037.g001
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Hemolytic activity assays
Defibrinated sheep blood (from Biomedics or Oxoid) or
human blood from a volunteer (EG) was used in hemolytic
activity assays. The blood (5 ml) was centrifuged and the cells
washed thoroughly with phosphate-buffered saline (PBS). Cells
were collected by centrifugation at 5,000 rpm for 10 min in a
Sorvall SS-34 rotor, resuspended in 5 ml of PBS, and stored at
4uC. The number of red blood cells (RBC) was adjusted to
ensure total lysis with distilled water. Then, 0.6 ml of RBC
suspension in PBS was mixed with 0.6 ml of CSA-13 solution
using final drug concentrations proportional to the MIC. The
mixtures were incubated at 37uC for 1 h and centrifuged at
8006g for 5 min; the supernatant was then removed and the
A550 determined. The percentage of hemolytic activity of the
drug at different concentrations was estimated as (A2A0/Amax2
A0)6100, where A0 is the absorbance associated with the
background hemolysis occurring during incubation with PBS,
and Amax the absorbance at 100% hemolysis after incubation in
distilled water (for sheep blood) or 0.01% Triton X-100 (for
human blood) [19].
Circular dichroism spectra
Circular dichroism (CD) spectra were recorded at 20uC
using a J-810 spectropolarimeter (Jasco Corporation) equipped
Table 1. Streptococcal strains used in the present work, and associated CSA-13 MIC values.
Bacterial species/strainsa
Relevant characteristics
(MIC; mg/ml)b CSA-13 susceptibility Reference/Origind
(MIC; mg/ml)c
Mitis group
Streptococcus pneumoniae
R6 Unencapsulated laboratory strain, lytA+ 4 (1) [57]
P103 Unencapsulated laboratory strain,
lytA::aphIII
4 (1) This study
Spain23F-1 Serotype 23F, lytA+
(PEN, 1–2; TET, 8; CHL, .8)
4 (1) [58]
8249 Serotype 19A, lytA+
(PEN, 6; IPM, 0.35; VAN, 0.4)
4 (1) [59]
S3 Serotype 23F, DlytA
(PEN, 8; CTX, .16; VAN, 0.5)
8 [60]
SPC2162 Serotype 19A, lytA+
(PEN, 16)
8 [61]
SPC2552 Serotype 23F, lytA+
(PEN, 32)
4 [61]
ST942 Non-typeable, lytA+ 8 [24,62]
Streptococcus sp. strain
782/96
lytA+
(PEN, 0.25; TET, 128; ERY, .128)
(1) [37]
Streptococcus sp. strain
11923/96
lytA+
(PEN, 8; TET, 0.5; ERY, 4)
(1) [37]
Streptococcus gordoniiT Type strain (2) CECT
Streptococcus mitis NCTC 12161T Type strain (2) NCTC
Streptococcus oralis NCTC
11427T
Type strain (1) NCTC
Streptococcus oralisT
(pLSE5)
Type strain, lytA+ (1) [27]
Streptococcus pseudopneumoniae CCUG
49455T
Type strain, lytA+ (1) [63], CCUG
Streptococcus sanguinis
CECT 480T
Type strain (2) CECT
Mutans group
Streptococcus mutans
CECT 479T
Type strain (1) CECT
Pyogenic group
Streptococcus agalactiae
CECT 183T
Type strain (1) CECT
Streptococcus pyogenes
CECT 985T
Type strain (1) CECT
aT, type strain.
bCHL, chloramphenicol; CTX, cefotaxime; ERY, erythromycin; IPM, imipenem; PEN, penicillin; TET, tetracycline; VAN, vancomycin.
cMICs in C medium are indicated in parentheses.
dCCUG, Culture Collection, University of Go¨teborg; CECT, Coleccio´n Espan˜ola de Cultivos Tipo; NCTC, National Collection of Type Cultures.
doi:10.1371/journal.pone.0101037.t001
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with a Peltier holder. Far UV spectra were recorded in
0.1 cm-pathlength cells at a protein concentration of 0.16 mg/
ml [20]. The observed ellipticities were converted to mean
residue ellipticities [h] assuming a mean molecular mass per
residue of 114.8 Da after subtraction of the buffer or the ligand
spectra.
Statistical analyses
The two-tailed Student t test, performed using GraphPad InStat
version 3.0 software (GraphPad Software, San Diego, CA), was
used to determine the differences between means. Data are
representative of results obtained from at least three independent
experiments.
Results
Determination of CSA-13 MICs for the streptococcal
strains
Planktonic cultures of eight pneumococcal strains (including
the R6 unencapsulated laboratory strain and multidrug-resistant
clinical isolates) and of several primary or opportunistic
pathogens (Table 1), were tested for their sensitivity to CSA-13.
MICs were determined in Mueller-Hinton broth supplemented
with 2.5% lysed horse blood, and in C medium in the absence of
such blood since some authors have reported that certain
antimicrobial agents, such as miltefosine, bind to serum
components, reducing the effective concentration [21,22]. CSA-
13 showed potent antimicrobial activity against all the strepto-
coccal strains tested. MICs of 1–2 mg/ml were recorded in the C
Figure 2. Effect of CSA-13 on streptococcal species. Exponentially growing cultures were incubated in C+Y to an A550 of about 0.2. CSA-13 was
then added to aliquots of the cultures and incubation continued without shaking at 37uC. (a) S. pneumoniae R6. (b) S. pneumoniae Spain23F-1. (c)
Streptococcus sp. strain 11923/96. (d) S. pseudopneumoniae. (e) S. gordonii. (f) S. mitis. (g) S. sanguinis. (h) S. mutans. (i) S. agalactiae. (j) S. pyogenes.
Solid circles represent untreated, control cultures. CSA-13 was added (open symbols) at the concentrations: triangles, 1 mg/ml; circles, 10 mg/ml;
squares, 25 mg/ml. (k) Lytic effect of CSA-13 (10 mg/ml; open symbols) added to a culture of the pneumococcal strain R6 at the times indicated by the
arrows. (l) Bactericidal effect of CSA-13 on different streptococcal species (initial A550 corresponding to 1–2610
8 CFU/ml). Grey, dashed and blackened
bars correspond, respectively, to bacterial survival after 0, 2 h, and 6 h incubation in the presence (+) or absence (–) of the ceragenin (10 mg/ml).
Standard error bars are shown.
doi:10.1371/journal.pone.0101037.g002
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medium tests, and of up to 8 mg/ml in the lysed blood-containing
medium (Table 1).
Bactericidal and lytic effects of CSA-13 on streptococcal
cultures
Time-kill experiments were performed with CSA-13 and
various streptococcal species. CSA-13 triggered rapid pneumo-
coccal lysis at concentrations of $5 mg/ml when added during the
early exponential phase of growth (Figs. 2a and b). Interestingly, a
lytic effect was recorded in S. pneumoniae R6 when the drug was
added during the mid-exponential and stationary phases (Fig. 2k).
The difference between the MIC and the concentration of
ceragenin with in vitro activity can be explained in that the efficacy
of the antibiotic depends inversely on the initial density of
microorganisms [23]. The multidrug-resistant Spain23F-1 strain
also underwent lysis in the presence of CSA-13, even at
concentration of 2.56MIC (lower than that causing lysis in the
R6 strain). Interestingly, S. pseudopneumoniae and Streptococcus sp.
11923/96, which synthesize a partly active LytA-like autolysin
[24], also lysed rapidly in response to CSA-13 (Figs. 2c and d).
Other streptococci that underwent lysis after exposure to CSA-13
(10 mg/ml) were S. gordonii, S. mutans and S. agalactiae. Moreover,
Figure 3. Fluorescence microscopy images of S. pneumoniae R6 cells either untreated (panels a–c) or treated with CSA-13 (100 mg/
ml; 3 h) (panels d–f) and stained with the BacLight bacterial viability kit. Live and non-viable bacteria fluoresce green (b, e) and red (c, f)
respectively. Panels a and d are phase contrast micrographs. The arrows indicate cells treated with CSA-13 and lacking any cytoplasmic content. Panel
d (enlarged inset) shows four apparently empty cocci. Some cellular material appears to be undergoing release from two bacteria (arrowheads).
doi:10.1371/journal.pone.0101037.g003
Figure 4. Growth and lysis curves and survival of S. oralis (a, b) and S. oralis (pLSE5) expressing LytA (c, d) treated with CSA-13. Cells
were grown in C+Y at 37uC to an A550 of about 0.2. CSA-13 was then added to an aliquot of the culture and incubation continued without shaking at
37uC. Solid circles represent untreated control cultures. CSA-13 was added (open symbols) at 2.5 mg/ml (triangles) or 10 mg/ml (circles). For panels b
and d, grey, dashed and blackened bars correspond, respectively, to bacteria survival after 0, 2 h, and 6 h incubation in the presence (+) or absence (–)
of the ceragenin (10 mg/ml). Standard error bars are shown.
doi:10.1371/journal.pone.0101037.g004
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the growth of S. mutans and S. agalactiae was slowed at 1 mg/ml of
CSA-13, and the cultures lysed with concentrations ranging
between 2.5 and 10 mg/ml. S. mitis, S. sanguinis and S. pyogenes
stopped growing when treated with CSA-13, but did not lyse
(Figs. 2f, g and j). Interestingly, even in the absence of lysis, CSA-
13 showed notable bactericidal activity, causing a fall in bacterial
survival of up to 4–5-log units after 6 h incubation with 10 mg/ml
(Fig. 2l).
It was noted that bacterial growth stopped but lysis did not
occur when pneumococcal cultures were treated with concentra-
tions of CSA-13 $25 mg/ml. Nevertheless, micrographs of strains
treated with 100 mg/ml CSA-13 showed only non-viable bacteria
represented by cocci that apparently lacked intracellular content
(Fig. 3d–f).
CSA-13 triggers LytA activity
Bile (or sodium deoxycholate) solubility is one of the classic tests
for distinguishing S. pneumoniae from all other a-hemolytic
streptococci [25]. NAM-amidase LytA is responsible for the
solubilization of pneumococci by deoxycholate [26]. To determine
whether NAM-amidase LytA is involved in the lytic effect of CSA-
13, cultures of S. oralis (pLSE5) expressing the pneumococcal LytA
autolysin [27], and S. oralis, which lacks the lytA gene, were
incubated with CSA-13 in the early exponential phase of growth.
S. oralis (pLSE5) underwent lysis after exposure to $2.5 mg/ml, a
response that contrasted to that shown for S. oralis (Figs. 4a and c).
Moreover, when treated with 10 mg/ml CSA-13 over a 6 h period,
S. oralis (pLSE5) showed a viable count reduction of 3-logs
compared to a 2-log reduction for S. oralis (which lacks lytA)
(Figs. 4b and d). These results suggest that LytA may be
responsible for as much as 1-log unit of the cell killing observed.
The lytA mutant strain P103, which underwent no lysis in the
stationary phase of growth either in the absence or presence of the
CSA-13, did undergo lysis after the addition of purified LytA
(10 mg/ml) and then CSA-13 (5 mg/ml) (Fig. 5a) –i.e., it was
‘‘cured’’ [28] to the wild-type phenotype. This provides further
evidence that the lysis events observed were LytA-mediated. In
addition, a rapid loss of viability was observed when the P103
strain was incubated with CSA-13 (a ca. 4-log reduction in viable
cells after 3 h of treatment), even in the absence of any detectable
autolysis (Fig. 5a).
The inhibitory effect of CSA-13 on the lysis of pneumococci
when at concentrations $25 mg/ml may be due to a direct (or
indirect) inhibitory effect of the drug on LytA activity. In vitro
experiments showed that ceragenin caused a dose-dependent
inhibition of NAM-amidase LytA activity (Fig. 5b). A reduction in
LytA activity of 85% was observed at 25 mg/ml CSA-13. CD
spectroscopy showed that a clear structural alteration of LytA takes
place upon incubation with 50 mg/ml CSA-13 (Fig. 5c). In the far-
UV region of the LytA spectrum, two negative bands were seen at
210 and 230 nm, a known spectral characteristic [29]. The low
absolute value of the ellipticity at 210 nm, and the negative band
at 230 nm, reflect a high contribution of aromatic amino acid side
chains. Moreover, choline addition to LytA (Fig. 5c) produces a
positive band at 224 nm, a red shift in the small negative band at
230 nm, and a slight increase in the negative ellipticity at 210 nm
[29]. Interestingly, the changes in the CD spectrum of LytA
incubated with CSA-13 were partially reverted by choline
chloride, indicating that the ceragenin mainly affects the aromatic
acid-rich, C-terminal domain of the NAM-amidase responsible for
cell wall binding [11]. These results taken together are in
accordance with the inhibition of lysis in pneumococcal cultures
treated with high concentrations of CSA-13 (Fig. 2).
Figure 5. Triggering of the LytA autolysin by CSA-13. (a) An
exponentially growing of S. pneumoniae strain P103 (lytA::aphIII) was
incubated in C+Y medium with (open symbols) or without (solid
symbols) pure LytA enzyme (10 mg/ml) for 30 min at 37uC. The culture
was then diluted to an A550 of 0.2 and divided into two portions. CSA-13
was added at 5 mg/ml (diamonds) to one while the other was left
untreated (circles). Incubation was continued at 37uC. Survival of the
culture treated only with CSA-13 was determined by plating at different
incubation times (dotted line). (b) Effect of CSA-13 on the activity of cell
wall hydrolase LytA using radioactively labeled pneumococcal cell walls
as substrate. Data represent the percentage activity of LytA in the
absence of CSA-13 and are the means of three independent
experiments. (c) CD spectra of LytA in the far-UV region in the absence
and presence of CSA-13 (50 mg/ml) and/or 48 mM choline chloride
(cho).
doi:10.1371/journal.pone.0101037.g005
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Effect of CSA-13 on biofilm formation by S. pneumoniae
To test the capacity of CSA-13 to destroy pneumococcal
biofilms, the percentage of biofilm remaining after treatment with
different concentrations of CSA-13 above the MIC for 1 h at 34uC
was determined. At concentrations of $10 mg/ml, CSA-13
effectively disintegrated the biofilms produced by S. pneumoniae
R6 (Fig. 6a). However, they had no apparent effect on the biofilm
produced by the lytA mutant P103, as determined by crystal violet
staining, although it killed more than 95% of the pneumococci
present, as estimated by enumeration of viable counts (Fig. 6b).
The viability of pneumococcal biofilms in the presence of CSA-13
was also examined by CLSM (Fig. 7). Biofilms of S. pneumoniae R6
grown on glass plates for 12 h at 34uC were treated with CSA-13
(5 or 25 mg/ml) for 90 min and the cells stained using the bacterial
viability BacLight kit. A noticeable decrease in biofilm thickness
was observed after treatment with 5 mg/ml of CSA-13 (Fig. 7b),
and almost all biofilm cells were killed (i.e., they showed red
fluorescence) when a dose of 25 mg/ml was used (Fig. 7c).
Hemolytic activity of CSA-13
CSA-13 showed relatively little hemolytic activity at concentra-
tions equivalent to the MIC in most of the streptococci examined
(Table 2). Indeed, less than 10% hemolysis was recorded in human
blood at CSA-13 concentrations of #10 mg/ml. Total permeabi-
lization of RBC was only achieved with $50 mg/ml CSA-13 (not
shown). All concentrations of CSA-13 below 50 mg/ml showed less
lytic activity against human RBC than against sheep RBC
(Table 2).
Discussion
S. pneumoniae is a major human pathogen and a leading cause of
pneumonia, bacteremia and meningitis in adults, and of otitis
media in children. Given the rapid dissemination of antibiotic
resistance in S. pneumoniae, along with other Gram-positive
pathogens quoted as ‘‘superbugs’’ [30], new therapeutic strategies
are needed to fight the increasing prevalence of multidrug-resistant
Figure 6. Disaggregation of biofilms in the presence of CSA-13. S. pneumoniae R6 (a) and P103 (lytA::aphIII) (b) were inoculated into 200 ml of
C medium in the wells of a microtiter plate (4.56106 CFU/ml). After biofilm development (6 h at 34uC), CSA-13 was added at different concentrations,
and incubation allowed to proceed for 1 h at 34uC before staining with crystal violet to quantify biofilm formation (open bars). Percentage viability
(solid lines) after treatment with CSA-13 was determined by plating on blood agar plates. Standard error bars are shown. Asterisks indicate a P value,
0.05.
doi:10.1371/journal.pone.0101037.g006
Figure 7. Confocal laser scanning microscopy image of the viability of biofilm-grown S. pneumoniae R6 in the presence of CSA-13.
Pneumococcal strains (4.56104 CFU) were grown on glass-bottom dishes (WillCo-dish) in 2 ml of C medium for 12 h at 34uC. The pneumococcal
biofilms were rinsed with C medium to remove non-adherent bacteria, and then incubated with CSA-13 at 5 mg/ml (b) or 25 mg/ml (c) for 90 min at
34uC. Panel a shows untreated control biofilm. Cells in the biofilms were stained with the BacLight bacterial viability kit to reveal living (green) and
dead (red) bacteria.
doi:10.1371/journal.pone.0101037.g007
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bacterial infections. The bacterial membrane remains an interest-
ing target since it represents a well-conserved structural element
across Gram-positive and indeed Gram-negative bacteria, and
because resistance to drugs that attack the membrane would
require major –and likely unviable– changes in membrane
structure and composition [31]. In fact, CSA-13 resistance in
Gram-negative bacteria only correlates with membrane modifica-
tions that are unstable in the absence of the drug, and in Gram-
positive Staphylococcus aureus no CSA-13 resistance has ever been
seen, at least under in vitro conditions [32].
In this study, we have analyzed the susceptibility of S. pneumoniae
and other pathogenic streptococci to CSA-13, the most potent
member of the ceragenin class. For all the streptococci tested, the
MIC values were moderately higher in Mueller-Hinton broth
supplemented with 2.5% horse blood than in C medium (Table 1).
This is probably due to interaction with serum components
reducing the effective concentration of the drug in the former
medium. Interestingly, CSA-13 showed comparable activity
against the laboratory pneumococcal strain R6, the multi-resistant
clinical isolates as strains Spain23F-1 and 8249, the vancomycin-
tolerant strain S3, and the highly b-lactam-resistant strains
SPC2162 and SPC2552 (Table 1). The bactericidal activity of
CSA-13 against clinical isolates of resistant S. aureus and P.
aeruginosa strains was reported in earlier studies [31,33,34]. The
present results show the susceptibility of S. mutans and S. pyogenes to
CSA-13 to be similar to that of S. mutans Ingbritt and other clinical
isolates of these species [35,36].
CSA-13 showed a concentration-dependent activity against all
the pathogenic streptococci tested. In time-kill analyses, the
pneumococcal strains, S. pseudopneumoniae and Streptococcus sp.
11923/96 underwent autolysis in the presence of 2.5–20 mg/ml
CSA-13 (Figs. 2c, d). This is similar to that observed for
miltefosine, an alkyllysophospholipid derivative used for the oral
treatment of visceral leishmaniasis [22]. These strains synthesize
an autolysin closely related to the pneumococcal autolytic NAM-
amidase LytA but in contrast with the behavior of the ‘‘typical’’ S.
pneumoniae autolysin, these enzymes are inhibited by 1% sodium
deoxycholate [22,37]. This lytic effect of CSA-13 was also
observed in S. gordonii, S. mutans and S. agalactiae, presumably
caused by the triggering of bacterial and/or prophage peptido-
glycan hydrolases [38–40]. In contrast, other streptococcal species
(i.e., S. mitis, S. sanguinis, and S. pyogenes) did not lyse with CSA-13.
However, even when no bacterial lysis was observed, CSA-13
efficiently killed the streptococcal cells (Figs. 2, 4, and 5a).
Undisrupted cocci apparently lacking intracellular content were
detected after treatment of pneumococcal cells with 100 mg/ml
CSA-13 (Fig. 3d). Similar changes have previously been observed,
using transmission electron microscopy, in E. coli cells treated with
CSAs [41]. Changes indicating wall damage have also been
reported in P. aeruginosa after treatment with CSA-13, as
determined by atomic force microscopy [42]. In agreement with
the latter report, CSA-13 was here confirmed to show relatively
little hemolytic activity against RBC at concentrations near the
MIC for the present strains (Table 2). Cytotoxicity experiments
have shown CSA-13 to be mildly toxic to fibroblasts at 100 mg/ml,
but not at 75 mg/ml [43]. Interestingly, the cytolytic activity of
CSA-13 is greatly reduced in the presence of pluronic acid F-127;
consequently, it might be useful for combating streptococcal
infections in this combination [34,42,44].
The autolysis caused in pneumococcal cultures by CSA-13 (and
also in S. oralis cultures harboring the plasmid pLSE5 encoding
LytA) was due to the triggering of the LytA NAM-amidase, as
demonstrated by phenotypic ‘‘curing’’ experiments (Fig. 5a). The
rapid lysis of pneumococcal strains (and other streptococcal
cultures producing a LytA-like autolysin) is very reminiscent of
the lytic response of S. pneumoniae to the detergent action of sodium
deoxycholate (the bile solubility test) or miltefosine [22,25,26].
Since the mid 1970s it has been known that mild detergents, such
as sodium deoxycholate, or cell wall inhibitors such a b-lactams,
fosfomycin and D-cycloserine, cause the release of lipoteichoic
acid from the bacterial cell membrane in a number of streptococci
[45,46]. Pneumococcal lipoteichoic acid is a specific inhibitor of
the LytA NAM-amidase [47], and destabilization of the
lipoteichoic acid–LytA complex triggers bacterial autolysis [48].
It should be noted that ceragenins and sodium deoxycholate are
cholic acid-derivatives, and a similar response to both agents might
be anticipated [5]. Importantly, our results showed that CSA-13
possesses bactericidal activity even when no bacteriolysis occurs.
This is not completely unexpected since previous work [49] has
shown that, although an enzymatically active LytA autolysin is
required for b-lactams-promoted lysis (see above), pneumococci
are actually killed even though lysis fails to occur.
Bacterial biofilms are implicated in chronic and persistent
infections [50] due to the protection they offer against antibiotics
and host immune defenses [51–53]. Biofilm formation by S.
pneumoniae on abiotic and biotic substrates (such as adenoid and
mucosal epithelia) has been documented [54]. Our results reveal
noticeable bactericidal activity by CSA-13 against pneumococcal
Table 2. Hemolytic activity of CSA-13 on sheep and human blood.
CSA-13
(mg/ml) % Hemolytic activity
a
Sheep blood Human blood
0.05 7.4 0.0
0.1 8.6 0.0
0.5 13.4 0.1
1 21.1 0.3
2.5 32.9 1.4
5 41.7 3.1
10 52.7 9.0
25 58.7 20.1
aPercentage hemolytic activity estimated as (A2A0/Amax2A0)6100, where A0 represents background hemolysis occurring during incubation with PBS, and Amax the
absorbance at 100% hemolysis after incubation in distilled water (for sheep blood) or 0.01% Triton X-100 (for human blood).
doi:10.1371/journal.pone.0101037.t002
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cells growing in biofilms, a phenomenon associated with the
disintegration of biofilm structure (Figs. 6a and 7). However,
concentrations slightly higher than those required for bactericidal
activity against planktonic bacteria were required to remove
pneumococcal biofilms. Recent reports have shown that CSA-13 is
effective against biofilms formed by P. aeruginosa, Moraxella
catarrhalis, Helicobacter pylori, S. aureus and Enterococcus faecalis
[34,55,56].
In summary, CSA-13 is an efficient antimicrobial agent against
S. pneumoniae and other human streptococcal pathogens in vitro; it
also destroys pneumococcal biofilms in a very efficient manner.
This molecule warrants further investigation as a therapeutic
weapon for use against streptococci, particularly multidrug-
resistant pneumococci and strains causing biofilm-related infec-
tions.
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